Detecting the "Sham" in Speaker Programs

Mark Labovitz, Ph.D., MBA and Jeffrey DiFrancesco, M.Sci., M.Eng.

June 2, 2016

This paper explores whether the publically available Open Payments data can be employed, using the same factual basis as the Government in its March 2016 allegations against Novartis to detect potential "sham" speaker programs.

Labovitz, M. and DiFrancesco, J. 2016. Detecting the "Sham" in Speaker Programs. Life Science Compliance Update, U.S. EDITION, Volume 2.6, June 2016. pp. 9-14.

Blog Articles

Caveat User, Caveat Emptor - Issues from the Soft Under Belly of The CMS Data Sets
Read More >

Detecting the "Sham" in Speaker Programs
Read More >

“Open Payments – A New Source of Clinical Site Intelligence”
Read More >

Workshop Speaker, "Demonstrating Compliance to the Department of Justice"
Read More >

Coauthor, “Are Phase 3 Clinical Trials Really Becoming More Complex?”
Read More >

View All Company News >